Genetron Health Partners with Guizhou Province’s Dafang County to Lead Liver Cancer Early Screening Project
July 29 2021 - 4:35AM
Genetron Holdings Limited (“Genetron Health” or the “Company”,
NASDAQ: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today announced that it will work with Guizhou Province’s Dafang
County authorities to lead the “Early Screening for Regional Liver
Cancer Prevention and Containment Demonstration Project”. Backed by
the Central Committee of the Chinese Peasants and Workers
Democratic Party and guided by China’s National Cancer Center, this
project is a collective effort that will be carried out by the
Dafang County Health Bureau, the People’s Hospital of Dafang, and
Genetron Health.
The project seeks to push boundaries for leading cancer early
screening technologies, products, and services in China’s rural
markets, enabling healthcare efforts to reach a wider range of
people. This project represents Genetron Health’s latest efforts to
partner with local governments, following the Company’s previous
partnership with Wuxi’s Huishan district.
Genetron Health will work with its partners to carry out early
screening, diagnosis, treatment, follow-up screenings, and patient
management for high risk liver cancer groups in Guizhou’s Dafang
County. Genetron Health will establish a comprehensive cancer
prevention and containment model that prioritizes prevention, and
integrates it with long-term screening management, diagnosis, and
treatment.
HCCscreen™, Genetron Health’s blood-based early screening test
for hepatocellular carcinoma, will play a key role in this project.
HCCscreen™ leverages Genetron Health’s original technology,
Mutation Capsule, to simultaneously detect different biomarkers in
a blood sample without reducing sensitivity; the technology can
also be used repeatedly on the same blood sample. This enables it
to obtain more comprehensive, accurate information in a manner that
is not only simple, fast, and precise, but is also more accessible
for doctors and patients. In 2019, China’s National Cancer Center
used HCCscreen™’s liver cancer early screening liquid biopsy
technology in a large-scale prospective cohort study. According to
the project’s recently released data, HCCscreen™ was able to
achieve 88% sensitivity and 93% specificity in a prospective cohort
of 1,615 HBsAg positive patients, indicating performance superior
to that of studies using ultrasound and AFP detection
technology.
“Innovating medical technology begins with exploration, and
extrapolating scientific research results to the general public is
a core value of independent innovation. In response to the
government’s ‘Healthy China 2030’ campaign, we have made extensive
efforts to build a three-dimensional cancer prevention and
containment system,” said Sizhen Wang, Co-Founder and CEO of
Genetron Health.
“On one hand, we act as a driving force, working together with
various partners and stakeholders across the value chain to promote
the industry’s development. On the other hand, we use original
technology to move precise cancer diagnosis forward to the early
screening stage, enabling the prevention and containment of cancer
across the entire cycle. More importantly, we are able to deeply
penetrate local markets and make technology accessible to a wider
population, enabling better, more equitable protection of people’s
health,” concluded CEO Wang.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”)
(Nasdaq:GTH) is a leading precision oncology platform company in
China that specializes in cancer molecular profiling and harnesses
advanced technologies in molecular biology and data science to
transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding HCCscreen™ and Mutation Capsule, which involve risks and
uncertainties that could cause the actual results to differ
materially from the anticipated results and expectations expressed
in these forward-looking statements. These statements are made
under the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Statements that are not
historical facts, including statements about the Company’s beliefs
and expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties, and a number
of factors could cause actual results to differ materially from
those contained in any forward-looking statement. In some cases,
forward-looking statements can be identified by words or phrases
such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. Further
information regarding these and other risks, uncertainties or
factors is included in the Company’s filings with the SEC. All
information provided in this press release is as of the date of
this press release, and the Company does not undertake any duty to
update such information, except as required under applicable
law.
Investor Relations ContactUS:Hoki LukHead of Investor
RelationsEmail: hoki.luk@genetronhealth.comPhone: +1 (408)
891-9255
Media Relations ContactYanrong ZhaoGenetron
Healthyanrong.zhao@genetronhealth.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Apr 2023 to Apr 2024